Meropenem-Nacubactam Activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a Neutropenic Murine Lung Infection Model.
Nacubactam is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor under development for the treatment of serious Gram-negative infections. Herein, we assessed the efficacy of the human-simulated epithelial lining fluid (ELF) exposure of nacubactam in combination with meropenem against AmpC-overproducing (n = 4) and KPC-expressing (n = 3) Pseudomonas aeruginosa isolates in the neutropenic murine lung infection model. Meropenem, nacubactam, and meropenem-nacubactam (1:1 concentration ratio) MICs were determined in triplicate using broth microdilution. Regimens that provided ELF profiles mimicking those observed in humans given nacubactam 2g q8hr (1.5hr infusion) alone and in combination with a sub-therapeutic ELF exposure of meropenem were administered 2hrs after inoculation. Efficacy was assessed as the change in log10CFU/lung at 24hr compared with 24hr meropenem monotherapy. Meropenem, nacubactam, and meropenem-nacubactam MICs were 8 - >64, 128 - >256, and 2 - 16 mg/L respectively. Meropenem and nacubactam monotherapy groups demonstrated bacterial growth over 24hrs for each isolate. Against AmpC-overproducing and KPC-expressing P. aeruginosa isolates, meropenem-nacubactam combination resulted in -2.73 ± 0.93 and -4.35 ± 1.90 log10CFU/lung reduction respectively, relative to meropenem monotherapy. Meropenem-nacubactam combination showed promising in vivo activity against meropenem-resistant P. aeruginosa, indicative of a potential role for the treatment of infections caused by these challenging pathogens.